Thurston Springer Miller Herd & Titak Inc. Lowers Holdings in Medtronic PLC $MDT

by · The Markets Daily

Thurston Springer Miller Herd & Titak Inc. lowered its position in Medtronic PLC (NYSE:MDT – Free Report) by 92.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,912 shares of the medical technology company’s stock after selling 24,193 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Medtronic were worth $182,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1248 Management LLC purchased a new position in shares of Medtronic during the first quarter valued at $26,000. Delos Wealth Advisors LLC purchased a new stake in Medtronic in the second quarter worth about $27,000. Twin Tree Management LP bought a new position in Medtronic during the 1st quarter worth about $29,000. Activest Wealth Management increased its position in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the period. Finally, GFG Capital LLC purchased a new position in Medtronic during the 2nd quarter valued at about $36,000. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MDT shares. Robert W. Baird set a $103.00 price target on shares of Medtronic in a research report on Tuesday. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Wells Fargo & Company increased their target price on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medtronic in a report on Monday. Finally, UBS Group upped their price objective on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.11.

Check Out Our Latest Report on Medtronic

Medtronic Price Performance

NYSE MDT opened at $97.77 on Wednesday. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33. The firm’s fifty day simple moving average is $97.26 and its two-hundred day simple moving average is $93.18. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $125.34 billion, a P/E ratio of 26.35, a P/E/G ratio of 2.60 and a beta of 0.71.

Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the previous year, the business earned $1.26 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s payout ratio is presently 76.55%.

Medtronic Company Profile

(Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Featured Articles

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).